South Korea has formally designated brain-computer interfaces as a national future industry. On March 18, the Ministry of Science and ICT convened the 44th Comprehensive Biotechnology Policy Review Council and announced the “National R&D Strategy for the Future Brain Industry,” a framework that elevates BCI to the same strategic tier as AI, quantum computing, and semiconductor technology in the country’s industrial planning.
Minister Baek Kyunghoon framed the announcement in competitive terms. “We will secure technological leadership in BCI, a core technology that will change the world in 10 to 20 years,” he said. The subtext was clear: South Korea is watching the US and China pull ahead in neurotechnology and has decided it cannot afford to be a spectator.
Seven Missions
The strategy is structured around seven mission areas, each targeting a distinct clinical or commercial application for BCI technology:
- Machine control for patients with paralysis
- Treatment for dementia and Parkinson’s disease
- Restoration of sensory functions, including vision
- Artificial limbs controlled by neural signals
- Wearable robots driven by brain-computer interfaces
- Ultra-immersive virtual reality and augmented reality
- Defence applications
The breadth is deliberate. Rather than concentrating on a single use case, South Korea is treating BCI as a platform technology with applications across healthcare, consumer electronics, and national security. For each mission, the government plans to assemble integrated teams spanning industry, academia, research institutes, and hospitals, mirroring the consortium approach that has driven Korea’s success in semiconductors and display technology.
Full-scale mission-oriented project funding is scheduled to begin in 2027, building on what the ministry describes as over 30 years of accumulated brain research. The government has also signalled plans to form a national BCI alliance linking research institutes, startups, and established companies by sector.
Two Tracks: Invasive and Non-Invasive
The strategy draws a clear line between two development paths. For invasive BCI, where electrodes are implanted directly in brain tissue, the government will focus on achieving clinically stable outcomes in areas where regulatory barriers are highest — spinal cord injury, locked-in syndrome, and visual impairment. The emphasis is on building a rigorous clinical evidence base that can withstand international regulatory scrutiny.
For non-invasive BCI, the approach is faster and more commercially aggressive. The government sees wearable devices as a platform for early commercialisation not just in healthcare but in entertainment, education, and defence. The logic is that non-invasive systems face fewer regulatory hurdles and can generate revenue and industry expertise while the harder clinical work on implantable devices continues in parallel.
Korea’s Existing BCI Ecosystem
South Korea is not starting from zero. The country hosts the annual International Conference on Brain-Computer Interface, now in its fourteenth year. Korea University’s BCI lab, led by Seong-Whan Lee, is one of the most prolific academic BCI research groups in Asia.
On the industry side, Ybrain — a Seoul-based neurotech company originally focused on transcranial direct current stimulation for depression — was selected in 2025 as the lead R&D partner for a government-funded project developing wearable robots controlled by minimally invasive BCI. The Ministry of Trade, Industry and Energy committed approximately 6 billion won ($4.6 million) to the three-year effort, which aims to enable patients with complete paralysis to control autonomous wheelchairs using neural signals. It is the first project in Korea to use minimally invasive BCI for rehabilitation robotics.
Hyundai Motor has also invested in BCI device development, signalling interest from Korea’s largest industrial conglomerates.
The Competitive Context
The announcement comes at a moment when the global BCI race is intensifying. China approved the world’s first commercially available implantable BCI this month. The United States has Neuralink, Synchron, Paradromics, and BrainGate all advancing through clinical trials. The EU is classifying BCIs as high-risk AI systems under its AI Act.
South Korea’s strategy acknowledges this reality explicitly. The ministry cited both Neuralink’s clinical progress and China’s commercial approval as motivating factors. The response is characteristically Korean: a government-coordinated industrial strategy, public-private consortia, and mission-driven R&D funding designed to compress development timelines.
What It Means
South Korea is the third major economy, after China and the United States, to publish an explicit national BCI strategy with dedicated funding and mission targets. The approach differs from both. China’s strategy is top-down industrial policy with aggressive commercialisation timelines and state-directed capital. The American model is market-driven, with companies like Neuralink raising private capital and navigating FDA pathways independently. Korea’s model sits between the two: government-directed mission framing with industry execution, backed by public R&D funding.
The seven-mission structure also signals something important about how Seoul views BCI. This is not being treated as a healthcare technology alone. The inclusion of defence, VR/AR, and wearable robotics positions BCI as a general-purpose capability layer, much the way Korea treated 5G and semiconductor fabrication in earlier industrial cycles. Whether the funding matches the ambition remains to be seen. The strategy document sets the direction; the 2027 budget allocation will determine whether it has teeth.